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Nonhypotensive Low-Dose Nesiritide Has Differential Renal Effects Compared
With Standard-Dose Nesiritide in Patients With Acute Decompensated
Heart Failure and Renal Dysfunction
To the Editor: Brain natriuretic peptide (BNP) is a cardiac
peptide with vasodilating, renin-inhibiting, natriuretic, and di-
uretic properties (1). Human recombinant BNP (nesiritide) has
been approved by the Food and Drug Administration for the
management of acute decompensated congestive heart failure
(CHF) (2). The standard recommended dose of nesiritide is a
bolus of 2 g/kg followed by infusion of 0.01 g/kg/min.
Although preclinical studies have demonstrated the renal-
enhancing effects of systemic intravenous (IV) administration of
BNP, the clinical trials that led to the Food and Drug Adminis-
tration approval of BNP for the management of acute CHF have
been conflicting with regards to the renal-enhancing properties of
BNP (2–4). A recent study by Wang et al. (5) indicates that the
standard recommended dose of nesiritide does not improve renal
function in patients treated for acute decompensated CHF. Fur-
thermore, a meta-analysis of the clinical trials suggested that
nesiritide might even be detrimental to renal function in patients
with acute decompensated CHF (6). One explanation for the
discrepancy between the preclinical and clinical data could be in
part that the dose used in these clinical studies resulted in
significant decreases in blood pressure (BP) and hence renal
perfusion pressure, attenuating the renal-enhancing effects. Sup-
porting this hypothesis is our previous study in experimental CHF,
which demonstrated that a low-dose subcutaneously administered
BNP, which did not lower blood pressure, had a more beneficial
renal hemodynamic profile than a higher dose that lowered BP (7).
The objective of the current study was to determine whether
low-dose IV nesiritide would have greater renal-enhancing prop-
erties than standard-dose IV nesiritide in acute decompensated
CHF. To address this question, we performed a retrospective
review on consecutive patients admitted to Mayo Clinic Heart
Failure Hospital Service for acute decompensated CHF from July
2001 to December 2004 who received nesiritide at doses lower
than the standard dose. We identified a total of 15 patients: 13
received 0.005 g/kg/min and 2 received 0.0025 g/kg/min of
nesiritide without bolus. We also compared these results with a
group of patients (n  13) who received the standard dose of
nesiritide (2 g/kg bolus followed by 0.01 g/kg/min) and a group
of patients (n  12) who received diuretic therapy without
nesiritide, matching for ejection fraction and calculated creatinine
clearance (CrCl). Creatinine clearance was calculated using the
Modification of Diet in Renal Disease formula: CrCl  186.3 ·
sCr 1.154 · age 0.203 · 0.742 if female · 1.21 if black.
Results are expressed as mean  SEM. Unpaired Student t test
was used for comparisons between groups; comparisons within
each group were done using paired Student t test.
Baseline demographics including age, ejection fraction, calcu-
lated creatinine clearance, plasma creatinine, and blood urea
nitrogen (BUN) were similar among the three groups. The
background medical therapy was also similar. The patients who
received low-dose nesiritide had lower baseline systolic BP com-
pared with patients who received standard-dose or no nesiritide
(97  3 mm Hg vs. 121  6 mm Hg vs. 115  6 mm Hg;
p  0.005).
Low-dose nesiritide was well tolerated without a significant
decrease in systolic BP (from 97  3 mm Hg to 99  3 mm Hg;
p  0.05), whereas systolic BP decreased significantly with
standard-dose nesiritide (from 121  6 mm Hg to 112 6 mm
Hg; p  0.05) and no nesiritide (from 115  6 mm Hg to 106 
6 mm Hg; p  0.05).
Patients in the low-dose nesiritide group had improvement in
renal function as measured by improvement of plasma Cr recorded
at baseline documented before the start of IV therapy compared
with the values after IV therapy (Fig. 1). This improvement of
plasma creatinine was also associated with a decrease in BUN
(from 78  9 mg/dl to 57  8 mg/dl; p  0.005) in the low-dose
nesiritide group. Renal function as measured by plasma creatinine
and BUN did not improve in the standard-dose nesiritide and
no-nesiritide groups. Patients in the low-dose nesiritide group
received less furosemide dose compared with the standard-dose
nesiritide and no-nesiritide groups (150 39 mg vs. 389 71 mg
vs. 345  115 mg of furosemide) while achieving similar diuresis
(1,601  600 ml vs. 1,677  910 ml vs. 1,052  679 ml)
during the IV therapy period.
The mechanism of the associated improvement in renal func-
tion observed in the low-dose nesiritide group is most likely
multifactorial, and we hypothesize that the improvement was due
in part to the fact that systolic BP was not reduced in this group.
The significant reduction in systolic BP observed in the standard-
nesiritide and no-nesiritide groups may have resulted in activation
of counter-regulatory mechanisms, such as the sympathetic and
the renin-angiotensin systems, thus attenuating the renal enhanc-
ing properties of nesiritide. Supporting this hypothesis is a study by
Brunner-La Rocca et al. (8) that demonstrated that the sympa-
thoinhibitory effects of BNP were greater with low-dose (0.003
Figure 1. Plasma creatinine at baseline (open bars) and after therapy (solid
bars) with low-dose nesiritide (Low Nes), standard-dose nesiritide (Stan-
dard Nes) and no-nesiritide (No Nes) groups. *p  0.05 versus baseline.
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g/kg/min) infusion, which did not alter hemodynamics, as
compared with a higher dose (0.015 g/kg/min) infusion, which
reduced BP.
In conclusion, further prospective randomized controlled stud-
ies are warranted to test the efficacy of non-hypotensive low-dose
nesiritide such as 0.005 g/kg/min and the current dose of 0.01
g/kg/min without the bolus of 2 g/kg/min in enhancing renal
function in patients with acute decompensated CHF and renal
dysfunction as well as defining the mechanisms of the renal-
enhancing actions of such a strategy.
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A Biomarker of Myocardial Fibrosis Predicts Long-Term Response to
Cardiac Resynchronization Therapy
To the Editor: Serum concentrations of the carboxy-terminal
propeptide of procollagen type I (PICP), a peptide that is cleaved
from procollagen type I during the synthesis of fibril-forming
collagen type I (CTI), may provide indirect diagnostic information
on both the synthesis of fibril-forming CTI molecules and the
extent of myocardial deposition of CTI fibers (1). We investigated
whether PICP is related to the clinical long-term response to cardiac
resynchronization therapy (CRT) in heart failure (HF) patients.
Thirty-eight consecutive patients were prospectively studied.
All patients received CRT for New York Heart Association
(NYHA) functional class III/IV HF, left ventricular (LV) ejection
fraction (EF) 35%, and QRS 130 ms. Twenty healthy subjects
were included as control subjects.
Patients were evaluated at baseline and at the 1-year follow-up.
Evaluation included NYHA functional class, 6-min walk test,
blinded echocardiographic study with measurement of interven-
tricular and intraventricular dyssynchrony parameters (septal-to-
posterior-wall motion delay [SPWMD] and septal-to-lateral-wall
motion delay [SLWMD]), and obtaining of blood samples. At 1
year, patients were categorized as nonresponders if they died of
HF, were scheduled for heart transplantation, or did not increase
the distance walked in 6 minutes by 10%.
Serum PICP was determined by a sandwich enzyme-linked
immunosorbent assay (ELISA) (inter- and intra-assay variations
were 6.3% and 6.4%, respectively). The minimum analytical
detection limit was 1 g/l. Serum amino-terminal propeptide of
brain natriuretic peptide (NT-proBNP) was measured by ELISA
(inter- and intra-assay coefficients of variation lower than 2%).
Differences between baseline values and between final values in
the two groups of patients were analysed with the Mann-Whitney
U test for SLWMD, interventricular dyssynchrony, and NT-
proBNP and with the Student t test for unpaired data for the rest
of the quantitative variables. Intragroup comparisons between
baseline and final values were analyzed with the Wilcoxon test
(SLWMD, interventricular dyssynchrony, and NT-proBNP) and
with the Student t test for paired data for the rest of quantitative
variables. Categoric variables were analyzed by chi-square test.
Significant variables in univariate analysis were used in logistic
regression analysis to predict the probability of positive response to
CRT. A model was constructed using stepwise variable selection,
verified with the Hosmer-Lemeshow test. Receiver-operating
characteristic (ROC) curves allowed determination of the overall
performance for predicting a positive response to CRT. The results
are expressed as mean  SD.
At 1 year, 26 patients (68%) were considered responders to CRT
(Table 1). At baseline, nonresponders exhibited higher left ventricular
end-diastolic diameter (LVEDD) and lower SLWMD than respond-
ers (p  0.05). Baseline PICP was higher in responders than in
controls (p  0.01) and nonresponders (p  0.05). Baseline NT-
proBNP was higher (p 0.001) in the two groups of patients than in
controls (36  5 pg/ml). Baseline NT-proBNP was increased (p 
0.05) in responders compared with nonresponders.
Whereas EF, LV diameters, and the dyssynchrony parameters
decreased (p  0.05) at 1 year in responders, they remained
unchanged in nonresponders. At 1 year, PICP decreased (p 
0.005) in responders and increased (p  0.005) in nonresponders.
Whereas in responders PICP decreased in 21 patients (81%) and
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